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130Endovascular recanalization of infrapopliteal
occlusions in patients with critical limb ischemia
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Background: Endovascular therapies are increasingly used for treatment of critical limb ischemia (CLI). Infrapopliteal (IP)
occlusions are common in CLI, and successful limb salvage may require restoration of arterial ﬂow in the distribution of a
chronically occluded vessel. We sought to describe the procedural characteristics and outcomes of patients with IP
occlusions who underwent endovascular intervention for treatment of CLI.
Methods: All patients with IP interventions for treatment of CLI from 2006 to 2012 were included. Angiographic and
procedural data were compared between patients who underwent intervention for IP occlusions vs IP stenosis. Restenosis
was determined by Doppler ultrasound imaging. Limb salvage was the primary end point of the study. Additional end
points included primary patency, primary assisted patency, secondary patency, occlusion crossing success, procedural
success, and amputation-free survival.
Results: A total of 187 patients with CLI underwent interventions for 356 IP lesions, and 77 patients (41%) had in-
terventions for an IP occlusion. Patients with an intervention for IP occlusion were more likely to have zero to one vessel
runoff (83% vs 56%; P < .001) compared with interventions for stenosis. Compared with IP stenoses, IP occlusions were
longer (1186 86 vs 736 67 mm; P < .001) and had a smaller vessel diameter (2.56 0.8 vs 2.76 0.5 mm; P[ .02). Wire
crossing was achieved in 83% of IP occlusions, and the overall procedural success for IP occlusions was 79%. The overall
1-year limb salvage rate was 84%. Limb salvage was highest in the stenosis group, slightly lower in the successful occlusion
group, and lowest in the failed occlusion group (92% vs 75% vs 58%, respectively; P [ .02). Unsuccessfully treated IP
occlusions were associated with a signiﬁcantly higher likelihood of major amputation (hazard ratio, 5.79; 95% conﬁdence
interval, 1.89-17.7) and major amputation or death (hazard ratio, 2.69; 95% conﬁdence interval, 1.09-6.63).
Conclusions: Successful endovascular recanalization of IP occlusions can be achieved with guidewire and support catheter
techniques in most patients. In patients selected for an endovascular-ﬁrst approach for IP occlusions in CLI, this strategy
can be successfully implemented with favorable rates of limb salvage. (J Vasc Surg 2014;59:1300-7.)Critical limb ischemia (CLI) is associated with high
rates of limb loss and mortality. Within 6 months of presen-
tation with CLI, w25% of patients require major amputa-
tion.1 An estimated 250,000 major amputations are
performed annually in the United States and Europe,
resulting in a signiﬁcant socioeconomic burden and severe
reduction in quality of life indicators.2,3 Published rates of
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05 years, exceeding rates observed in any other form of
occlusive arterial disease.1,2
Although surgical revascularization has been the tradi-
tional treatment of choice for limb salvage in CLI, an
increasing number of centers are adopting an endovascular-
ﬁrst approach to limb salvage. Initial studies suggested similar
outcomes for these two strategies, especially among patients
with a life expectancy of <2 years.4,5 More recent investiga-
tions have described procedural outcomes, techniques, and
angiographic characteristics of lower extremity endovascular
interventions.6-9
Infrapopliteal (IP) occlusive disease is a major indepen-
dent contributor to morbidity and mortality among pa-
tients with CLI.10 Recent reﬁnements in endovascular
techniques have led to the development of new approaches
for endovascular treatment of IP occlusive disease among
patients with CLI.11 IP occlusions are common in this pa-
tient population and present signiﬁcant challenges for
endovascular intervention. Few data are available regarding
procedural and limb salvage outcomes of endovascular
treatment for IP occlusions.
We sought to describe our institutional experience with
endovascular management of IP occlusions and to quantify
the association of IP occlusion treatment with subsequent
limb salvage rates among patients with CLI. We hypothe-
sized that IP occlusions could be recanalized with a high
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that successful treatment of IP occlusions would be associ-
ated with acceptable rates of limb salvage.
METHODS
This study was approved by the University of California
Davis Medical Center Institutional Review Board.
Data source. The Peripheral Arterial Diseasee
University of California Davis Registry comprises all pa-
tients with a clinical diagnosis of peripheral arterial disease
who underwent diagnostic peripheral angiography or ther-
apeutic endovascular intervention at the University of Cal-
ifornia Davis Medical Center from 2006 to 2012. For this
study, the subset of patients in the registry with CLI who
underwent IP endovascular interventions (187 patients,
representing 22% of the total registry) were analyzed. Dur-
ing the same time period (2006-2012), 80 patients were
referred for surgical revascularization of critical IP disease,
including 33 for rest pain, 26 for minor tissue loss, and
21 for major tissue loss.
CLI was deﬁned as Rutherford category 4, 5, or 6 dis-
ease (deﬁned as ischemic rest pain, minor tissue loss, or ma-
jor tissue loss, respectively) with a reduced ankle-brachial
index (ABI) to a level of <0.4, an ankle systolic pressure
of <50 mm Hg, or a toe pressure of <40 mm Hg, based
on a review of clinic notes, history, physical examination,
noninvasive laboratory testing, and hospital discharge sum-
maries. Rutherford categories were deﬁned using published
criteria.12
Procedural approach. The general procedural ap-
proach to IP interventions included ipsilateral anterograde
or contralateral retrograde common femoral arterial access
with a sheath advanced into the distal superﬁcial femoral ar-
tery or popliteal artery to allow for better catheter/guide-
wire control and reduced contrast administration. Our
institutional practice has been to use retrograde “cross-
over” access in most cases to allow for visualization of
the entire inﬂow of the contralateral leg; this approach per-
mits treatment of disease at the iliac level if necessary. Addi-
tionally, in our experience, retrograde contralateral access
with ultrasound guidance and a micropuncture technique
is associated with lower rate of access site complications
than the antegrade approach.
The stenosis or occlusion was then crossed using a stan-
dard hydrophilic-tipped guidewire, such as PT Graphix or
PT2 (Boston Scientiﬁc, Quincy, Mass), and a low-proﬁle
catheter support, such as Quick Cross (Spectranetics, Colo-
rado Springs, Colo). For lesions where this initial hardware
could not successfully cross the occlusion, more supportive
devices/wires were then used at the operator’s discretion;
for example, Conﬁanza or Miracle Bros 6 (Abbott Vascular,
Abbott Park, Ill) or V18 Control (Boston Scientiﬁc). When
deemed appropriate, devices designed speciﬁcally for chronic
occlusions were used, including Outback (Cordis, Bridge-
water, NJ) and Crosser (Bard, Tempe, Ariz), although these
devices were used in only ﬁve cases.
In recent years, retrograde pedal or tibial access was oc-
casionally performed after failed attempts at antegraderecanalization of occlusions. In these cases, the dorsalis
pedis artery or distal posterior tibial artery was cannulated
using ﬂuoroscopic or ultrasound guidance and a 4F micro-
puncture dilator was advanced retrograde into the vessel. A
guidewire was then advanced through this dilator to the
distal cap of the occlusion, and attempts were made to
cross the lesion from below. Once the lesion was crossed
from a retrograde approach, the wire was snared from
above and externalized through the femoral arterial sheath.
The procedure was then completed from an antegrade
approach.
During the study period, all procedures were per-
formed by three members of the institutional Vascular
Center (three vascular surgeons and one interventional
cardiologist).
Data collection and deﬁnitions. Baseline data were
collected from a review of electronic medical record docu-
mentation and procedure notes. Ofﬁce notes before and af-
ter the procedure, the admission history, and physical
documentation were used to identify clinical presentation
as well as postprocedural outcomes and medical manage-
ment. This information was entered into a prespeciﬁed
case report form with standardized data entry. Two authors
(E.A., G.S.) reviewed all angiographic images to verify
lesion location, presence of chronic occlusion, extent of
calciﬁcation, and distal runoff. Quantitative angiography
(Xcelera; Philips Medical Systems, Andover, Mass) was per-
formed on all target lesions to evaluate the preintervention
percentage of diameter stenosis, lesion length, and refer-
ence vessel diameter.
Procedural data included whether the lesion was a
restenosis or reocclusion, the type of intervention, whether
a stent was placed, and whether the intervention involved
balloon angioplasty, cutting balloon angioplasty, excimer
laser, excisional or rotational atherectomy, or cryoplasty.
A nonocclusive stenosis was deﬁned as #99% stenosis
with antegrade ﬂow on angiography. Occlusions were
deﬁned as complete arterial occlusion and absence of ante-
grade ﬂow. Procedural success was deﬁned as <30% steno-
sis at the conclusion of the procedure, without a major
adverse event.13-15
During follow-up, deaths were identiﬁed through elec-
tronic documentation of clinic or inpatient notes as well as
the Social Security Death Index. Major amputation was
deﬁned as any amputation above the level of the ankle
joint. Lesion patency was monitored with serial ABI and
toe-brachial index measures and duplex ultrasound
(DUS) imaging at 0 to 30 days, 4 to 6 months, and 9 to
12 months. Loss of primary patency (PP) after the initial
revascularization was deﬁned as the presence of >50% ste-
nosis during repeat angiography for progressive tissue loss
or a surveillance DUS assessment indicating restenosis.
For each vessel segment, the highest peak systolic velocity
obtained was used as the sample measure. A peak systolic
velocity ratio $2.0 was used to deﬁne $50% stenosis at
each interval DUS examination.16,17
Outcomes. The primary study end point was limb
salvage, deﬁned as avoidance of a major amputation above
Table I. Baseline patient characteristics
Variablea
Occlusion
(n ¼ 77)
Stenosis
(n ¼ 110) P
Age, years 68 6 12 69 6 14 .9
Male 50 (65) 69 (62) .8
Body mass index,
kg/m2
27.2 6 6.3 27.0 6 5.4 .9
Heart failure 27 (35) 23 (21) .03
Diabetes 55 (71) 77 (72) .9
End-stage renal disease 19 (25) 21 (19) .4
Prior or current smoker 36 (47) 65 (60) .09
GFR, mg/dL 54 6 33 60 6 38 .2
Hypertension 63 (82) 97 (88) .2
Coronary artery disease 33 (44) 56 (51) .4
Stroke 13 (17) 29 (27) .1
Hemoglobin A1c, % 7.5 6 2.0 8.3 6 2.5 .2
Statin use 40 (52) 78 (71) .008
Rutherford class .01
4 11 (15) 36 (35)
5 52 (69) 56 (54)
6 12 (16) 12 (12)
ABIb 0.29 6 0.10 0.35 6 0.04 .2
Toe-brachial index 0.26 6 0.12 0.29 6 0.13 .2
PREVENT III score (0-10) 4.0 6 2.3 4.7 6 2.5 .05
FINNVASC score (0-4) 2.3 6 0.8 2.3 6 0.9 .9
ABI, Ankle-brachial index; GFR, glomerular ﬁltration rate; FINNVASC,
Finland National Vascular scoring system; PREVENT III, Prevention of
Infrainguinal Vein Graft Failure III scoring system.
aContinuous data are shown as mean 6 standard deviation and categoric
data as number (%).
bABI after censoring of noncompressible ABIs.
Table II. Angiographic characteristics
Variablea
Occlusion
(n ¼ 126)
Stenosis
(n ¼ 230) P
Length, mm 118 6 86 73 6 67 <.001
Vessel diameter, mm 2.5 6 0.8 2.7 6 0.5 .02
Preprocedure stenosis, % 100 78 6 23 <.001
Calciﬁcation .2
None-mild 97 (77) 191 (83)
Moderate-severe 29 (23) 39 (17)
Runoff <.001
0-1 105 (83) 129 (56)
2-3 21 (17) 101 (44)
Target vessel .004
Anterior tibial 57 (45) 68 (30)
Tibioperoneal trunk 25 (20) 54 (23)
Peroneal 35 (28) 64 (28)
Posterior tibial 9 (7) 44 (19)
aContinuous data are shown as the mean6 standard deviation and categoric
data as number (%).
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PP (<50% stenosis at any point during the follow-up
period), primary assisted patency (PAP; reintervention for
>50%-99% restenosis), secondary patency (SP; reinterven-
tion for reocclusion), occlusion crossing success, proce-
dural success, and amputation-free survival.
Data analysis. Median values with interquartile ranges
were used to describe continuous variables, and numeric
values with percentages were used for categoric variables.
Univariate analysis was used to identify differences between
occlusions and stenosis in CLI patients with IP disease.
Continuous variables were compared using the Wilcoxon
rank sum test. Categoric values were compared by the c2
or Fisher exact test. Kaplan-Meier analysis was used to
compare outcomes of major amputation and mortality
among the patient groups. All analyses were performed
using Stata 11.2 software (StataCorp LP, College Station,
Tex). A P value of <.05 was considered signiﬁcant.
RESULTS
During the study period, 187 patients (119 male, 68
female) underwent peripheral artery angiography and IP
intervention for management of CLI; of these, 77 (41%)
had an endovascular intervention for an IP occlusion. The
mean number of IP target vessels was 1.56 0.5 in the occlu-
sion group and 1.3 6 0.5 in the stenosis group (P ¼ .5).
Among the 77 patients in the IP occlusion group, 19
(25%) also had intervention in an IP stenosis vessel during
the same procedure to maximize distal runoff. In the overall
cohort, 56% of patients also had concomitant intervention in
a femoropopliteal lesion during the same procedure. Patients
undergoing intervention for an IP stenosis were more likely
to undergo concomitant superﬁcial femoral artery/popliteal
intervention (65%) than patients with interventions for IP
occlusions (47%; P ¼ .01). Interestingly, we found that pa-
tients who underwent multilevel interventions actually had
better limb salvage rates (92% at 1 year) than those who un-
derwent IP interventions only (75% at 1 year).
Baseline characteristics and cardiovascular risk factors
for the two groups are summarized in Table I. Compared
with the stenosis group, IP occlusion patients were more
likely to have a history of heart failure (35% vs 21%; P ¼
.03) and were less likely to be taking statin medications
(52% vs 71%; P ¼ .008) before the procedure. Patients
who underwent interventions for IP occlusions were
more likely to have Rutherford class 5 (69% vs 54%) or 6
(16% vs 12%; P ¼ .01) disease than patients in the stenosis
group. The baseline toe-brachial index values were similar
in both groups (0.26 6 0.12 for IP occlusion vs 0.29 6
013 for stenosis; P ¼ .2), as were ABIs after exclusion of
noncompressible readings (0.29 6 0.19 for stenosis vs
0.35 6 0.04 for IP occlusion; P ¼ .2). No signiﬁcant
between-group differences were noted in other demo-
graphic characteristics, including age, body mass index, his-
tory of diabetes, smoking history, renal function, end-stage
renal disease, or hemoglobin A1c. Scores according to the
Prevention of Infrainguinal Vein Graft Failure III (PRE-
VENT III) scoring system (4.0 6 2.3 for stenosis vs4.76 2.5 for occlusions; range, 0-10; P ¼ .05) and Finland
National Vascular (FINNVASC) scoring system (2.3 6 0.8
for stenosis vs 2.3 6 0.9 for occlusions; range, 0-4; P ¼ .9)
also did not exhibit any statistically signiﬁcant between-
group differences.18
Angiographic characteristics for each lesion are summa-
rized in Table II. Of the 356 lesions treated during the
study period, 126 (35%) were IP occlusions. IP occlusions
Table III. Procedural characteristics
Variablea
Occlusion
(n ¼ 126)
Stenosis
(n ¼ 230) P
Cutting balloon 8 (6) 31 (13) .04
Cryotherapy 8 (6) 11 (5) .5
Atherectomy <.001
Laser 28 (23) 9 (4)
Excisional 1 (1) 3 (1)
Rotational 0 5 (2)
Stent placed 10 (8) 5 (2) .009
Femoral access .1
Anterograde 11 (9) 34 (15)
Retrograde 115 (91) 198 (85)
Fluoroscopy time, min 36 6 18 30 6 16 .01
Total contrast, mL 171 6 93 168 6 96 .9
aCategoric data are shown as number (%) and continuous data as mean 6
standard deviation.
Table IV. Complication and success rates
Variablea
Occlusion
(n ¼ 126)
Stenosis
(n ¼ 230) P
Dissection 7 (6) 2 (1) .006
Perforation 4 (3) 1 (0.4) .05
Wire crossing success 104 (83) 230 (100) .001
Procedural success 99 (79) 228 (99) .001
30-day post-treatment ABI 0.71 6 0.20 0.73 6 0.18 .7
ABI, Ankle-brachial index.
aCategoric data are shown as number (%) and continuous data as mean 6
standard deviation.
Fig 1. Primary patency (PP) at 1 year. Expressed in percentage.
NAR, Number at risk; SE, standard error.
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.001), were more likely to have moderate-severe calciﬁca-
tion (23% vs 17%; P ¼ .20), and were associated with worse
preprocedural distal vessel runoff (83% vs 56% zero- or
one-vessel runoff; P < .001). The most common target
vessel in the IP occlusion group was the anterior tibial ar-
tery (45%), followed by the peroneal artery (28%).
Tables III and IV summarize the procedural character-
istics and outcomes for each lesion. Wire-crossing success
was 83% for IP occlusions, and the overall procedural suc-
cess was 79%. Procedural success also translated into hemo-
dynamic success, with 30-day postprocedural ABIs
increased to 0.71 6 0.20 for occlusion and 0.73 6 0.18
for stenosis. All patients with procedural and angiographic
success had an ABI improvement of >0.15 at 30 days post-
procedure. Patients who underwent intervention for IP oc-
clusions were more likely to be treated with laser
atherectomy (23% vs 4%; P < .001) and stent deployment
(8% vs 2%; P ¼ .009) than the stenosis group. There were
small but signiﬁcantly higher rates of dissection (5% vs 1%;
P ¼ .006) and perforation (3% vs 0.4%; P ¼ .05) among
the IP occlusion group. None of these complications
resulted in the need for urgent surgery. Fluoroscopy time
was greater in the occlusion group (366 18 vs 306 16 mi-
nutes; P ¼ .01). There was no difference in contrast use be-
tween groups (171 6 93 vs 168 6 96 mL; P ¼ .9).Kaplan-Meier curves for PP, PAP, and SP are shown in
Figs 1-3, respectively. Rates of patency (Figs 1-3) were
similar between the occlusion and stenosis groups until
200 days after the intervention, at which point the curves
diverged. At 1 year, IP occlusions were associated with a
signiﬁcantly higher risk of subsequent restenosis (hazard
ratio [HR], 1.8; 95% conﬁdence interval [CI], 1.15-
2.71) compared with IP stenosis lesions (Fig 1). The esti-
mated PP at 1 year was 30% for IP occlusions and 42%
for IP stenosis (P ¼ .04). At the 1-year follow-up, PAP
was 45% for IP stenosis lesions and 30% for IP occlusions
(P ¼ .01), and SP rates were 54% for IP stenosis vs 43%
for IP occlusions (P ¼ .02).
The 1-year limb salvage rate for the entire cohort was
84%. Limb salvage rates among patients who underwent
intervention for IP occlusions vs stenosis are depicted in
Fig 4. IP occlusions were further categorized into success-
ful (n ¼ 99) vs unsuccessful (n ¼ 27) interventions. The
Kaplan-Meier curves show the highest 1-year limb salvage
for patients with an intervention for an IP stenosis (92%)
and intermediate (75%) limb salvage rates among patients
with successful IP occlusion interventions. Unsuccessful
IP occlusion interventions were associated with a signiﬁ-
cantly lower 1-year limb salvage rate of 58% (P ¼ .02).
Compared with patients with IP stenosis, successful IP oc-
clusion recanalizations remained associated with an
increased risk of subsequent major amputation (HR,
2.88; 95% CI, 1.16-7.18). However, the hazard for ampu-
tation was greatest among patients with unsuccessful IP oc-
clusion recanalizations (HR, 5.79; 95% CI, 1.89-17.7)
compared with IP stenosis interventions.
At 1 year, the estimated amputation-free survival
(Fig 5) was 80% for IP stenosis interventions, 71% for suc-
cessful IP occlusions, and 54% for failed IP occlusions.
Fig 2. Primary assisted patency (PAP) at 1 year. Expressed in
percentage. NAR, Number at risk; SE, standard error.
Fig 3. Secondary patency (SP) at 1 year. Expressed in percentage.
NAR, Number at risk; SE, standard error.
Fig 4. Limb salvage rates at 1 year. NAR, Number at risk; SE,
standard error. *Standard error >10%.
Fig 5. Amputation-free survival at 1 year. NAR, Number at risk;
SE, standard error. *Standard error >10%.
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cantly higher rates of death or major amputation (HR,
2.69; 95% CI, 1.09-6.63; P ¼ .03) at 1 year compared
with the stenosis group.
Among the 27 unsuccessful IP occlusions, 13 (48%)
were the anterior tibial artery, 10 (37%) were the posterior
tibial artery, 3 (11%) were the peroneal artery, and 1 (4%)
was the tibioperoneal trunk. Five (19%) of the failed occlu-
sions were in patients with Rutherford 6 disease. Five
(19%) of the occlusions were crossed with a guidewire,
but despite multiple attempts at intervention, procedural
success (<30% residual stenosis) was not achieved. Self-
limited vessel injury (dissection or perforation) notrequiring urgent surgical intervention was noted in seven
(26%) of the failed IP occlusions. One patient (4%) with
a failed IP occlusion intervention subsequently underwent
surgical revascularization. Repeat endovascular therapy
was attempted in four of the patients, of which two were
successful; the repeat endovascular attempts were under-
taken within 1 week to 3 months after the initial attempt.
A total of 22 amputations were performed despite
attempted percutaneous revascularization; of these, 17
(77%) were initially successful (stenosis or occlusion) inter-
ventions that had progressive CLI. The median number of
Table V. Characteristics of unsuccessful vs successful
infrapopliteal (IP) occlusion endovascular interventions
Variablea
Occlusion
P
Unsuccessful
(n ¼ 27)
Successful
(n ¼ 99)
Diabetes 20 (74) 75 (76) .9
End-stage renal disease 9 (33) 30 (31) .8
Prior or current smoker 15 (56) 50 (51) .7
Length, mm 118 6 82 116 6 82 .9
Calciﬁcation .2
None-mild 19 (76) 77 (78)
Moderate-severe 8 (24) 22 (22)
Occlusion device used 2 (7) 3 (3) .2
Retrograde attempt 1 (4) 6 (6) .9
Fluoroscopy time, min 42 6 13 34 6 18 .05
Total contrast, mL 151 6 60 174 6 97 .5
aCategoric data are shown as number (%) and continuous data as mean 6
standard deviation.
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35. Before amputation, surgical revascularization was
offered to two patients; one patient had progressive disease
despite surgical revascularization necessitating amputation,
and the other patient declined surgical revascularization.
Surgical revascularization was not attempted in the other
patients due to a variety of factors: 11 (55%) had in-
adequate distal targets for bypass, 10 (50%) had multiple
cardiac and medical comorbidities making surgery prohib-
itively high-risk, 4 (20%) had uncontrolled lower extremity
infection, and 4 (20%) had prior vein harvesting with no
usable venous conduit. Among the 22 patients who subse-
quently required major amputation, review of postproce-
dural angiograms did not show any evidence of distal
embolization, propagation of dissection, or other compli-
cations that might have limited the options for subsequent
surgical bypass.
The characteristics of unsuccessful vs successful IP
occlusion interventions are reported in Table V. There
were no signiﬁcant between-group differences in baseline
patient characteristics. Specialized occlusion-crossing de-
vices were used with greater frequency in the unsuccessful
cohort (7% vs 3%), although this difference was not statis-
tically different (P ¼ .2). Use of retrograde access to
achieve recanalization of an IP occlusion was similar be-
tween the two groups (4% vs 6%; P ¼ .9). Among the seven
retrograde access attempts, six (86%) were successful in
crossing the lesion and thereby allowing for recanalization
of the IP occlusion.DISCUSSION
In this study, we report procedural and midterm out-
comes of patients with CLI who underwent endovascular
interventions for IP occlusions. Our data highlight three
important ﬁndings: (1) use of a standard guidewire tech-
nique with support catheters is associated with high
crossing success (83%) and high procedural success (79%)during recanalization of IP occlusions; (2) successful endo-
vascular intervention of IP occlusions is associated with
limb preservation and survival rates that are similar to inter-
ventions for IP stenosis; and (3) failure of attempted occlu-
sion recanalization is associated with a signiﬁcantly
increased risk of subsequent major amputation.
The few dedicated analyses of IP interventions among
patients with CLI have been limited by small sample size
and lack of detailed data on IP occlusion characteris-
tics.19-25 Odink et al19 performed a retrospective analysis
of 90 patients with CLI and 161 IP lesions; 65% of the le-
sions were occlusions. These investigators reported an
overall technical failure rate of 11%; however, they did
not stratify their outcomes by occlusion status. Our study
demonstrated a procedural failure rate of 1% in the stenosis
group vs 21% in the IP occlusion group. This technical fail-
ure rate for IP occlusions is not unexpected given the chro-
nicity of many of these occlusions, the long occlusion
lengths, and presence of signiﬁcant lesion calciﬁcation.
Compared with other dedicated IP investigations with
similar patient cohorts, our technical success/failure and
complication rates are comparable to those achieved using
dedicated occlusion crossing devices.10,26 Our ﬁndings
suggest that the standard guidewire technique with use
of a support catheter can be associated with a high success
rate in recanalization of IP occlusions.
Restenosis after intervention of femoropopliteal and
IP disease remains a consistent ﬁnding across many investi-
gations, particularly if the treated lesion was an occlu-
sion.27-30 IP lesions are associated with a particularly high
rate of restenosis, partly due to small reference vessel diam-
eter and long length of the treated lesions with extensive
plaque burden. In a series of 68 ischemic limbs undergoing
angioplasty for treatment of isolated IP disease, rates of
restenosis approached 40% at 3 months and 82% at
1 year,27 as assessed by serial DUS imaging and angio-
graphy. However, the need for reintervention was only
48% at 1 year. In another investigation of 77 IP arteries
of CLI patients with long-segment disease (average length,
184 mm), 65% of the intervened segments were occlu-
sions.30 At 3 months, 70% of the intervened segments
demonstrated reocclusion or >50% restenosis, as assessed
by angiography. Despite this high rate of restenosis, clinical
improvement with a marked reduction in ulcer size or a
reduction in rest pain, or both, was seen in 76%.30 In
another cohort of 73 patients with CLI undergoing an
IP intervention, the 1-year PP was 60%, freedom from rein-
tervention was 95%, and the limb salvage rate was 88%.31
Collectively, these investigations provide credence to
the concept that restenosis is of less clinical importance in
limb revascularization procedures because the goal of
CLI intervention is to provide adequate arterial perfusion
to meet the heightened metabolic demands of nonhealing
tissue.5 Once this demand is met and tissue healing has
occurred, restenosis or reocclusion may not be of clinical
consequence if adequate tissue healing has already
occurred. Consistent with these ﬁndings, we report SP
rates of 54% in the IP stenosis cohort and 43% with the
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reocclusion. Despite these suboptimal patency rates, our
overall limb salvage rate was 84%, which is comparable to
other reported rates.31
Limb salvage rates were highest in the subset of CLI
patients who underwent interventions for IP nonocclusive
stenosis. IP occlusions were associated with increased rates
of major amputation; however, we observed a gradient of
effect, with a signiﬁcantly higher rate of subsequent major
amputation among patients with failed attempts at recana-
lization of IP occlusions. Although the decision to inter-
vene on a given occlusion was made at the discretion of
each operator, many of these IP occlusion interventions
represented “last option” attempts at limb salvage. End-
stage renal disease was present in 25% of the IP occlusion
group, and 16% had Rutherford category 6 ischemia at
the time of presentation. Our analysis of the amputation
cohort supports this notion of “last option.” Surgical revas-
cularization was not felt to be a viable approach for 91% of
these patients due to absence of adequate venous conduit,
lack of distal targets, or severe cardiac and noncardiac
comorbidities yielding a prohibitive risk to surgery. Also
supporting the “last option” notion is the ﬁnding that rein-
tervention was attempted in <20% of this cohort. The data
from the current study would suggest, however, that
although patients with IP occlusions do represent a high-
risk cohort, percutaneous recanalization should be attemp-
ted because rates of limb salvage are favorable if success is
achieved. This ﬁnding has important clinical implications
and supports the recent use of more extreme methods to
achieve successful recanalization of IP occlusions, such as
the use of tibial/pedal access, when traditional antegrade
approaches fail. It also highlights the potential need for
better IP total occlusion devices to optimize the chances
of crossing success if standard guidewire and support cath-
eter techniques are unsuccessful.32
In the present investigation, use of laser atherectomy
was also more frequent for treatment of IP occlusions. Spe-
ciﬁc procedural aspects of laser atherectomy have previ-
ously been reported.33 In a retrospective single-center
study of 443 patients with CLI from IP stenotic or occlu-
sive lesions, or both,34 12-month PP and limb salvage rates
were compared among patients receiving angioplasty alone
(n ¼ 79), angioplasty with stenting (n ¼ 300), and laser
excimer therapy (n ¼ 64). At 12 months, the PP rates
were not statistically different among the groups, at 69%,
76%, and 75%, respectively (P ¼ not signiﬁcant). However
limb salvage rates were lower in the laser group (88%) vs
angioplasty alone (97%) or angioplasty with stenting
(99%) during the same time period. The authors concluded
that the relatively inferior limb salvage rates in the laser-
based intervention group was not unexpected because
these patients tended to have longer and more heavily
diseased lesions vs the focal lesions receiving angioplasty
or stenting, or both.34
In a prospective multicenter registry, the Laser Angio-
plasty for Critical Limb Ischemia (LACI) trial35 enrolled
155 CLI patients (41% with IP stenosis or occlusions, orboth) who were felt to be poor candidates for surgical
revascularization. This registry demonstrated a procedural
success rate of 86% and limb salvage rates of 93% at
6 months in patients with complex infrainguinal occlusive
disease. In the present study, the overall small sample size
of IP lesions undergoing laser debulking therapy precludes
deﬁnitive conclusions. However, prior34,35 and current
investigation demonstrates that laser debulking may serve
as a useful adjunctive therapy in CLI patients with complex
lesions or IP occlusions.
This study has several potential limitations. Because
these data are observational, there was potential selection
bias in choosing patients in whom operators were conﬁdent
of procedural success. Some patients may have had such
extensive disease that an attempt at endovascular interven-
tion was impractical. Given the multiple treatment modal-
ities, statistical power was insufﬁcient to make any ﬁrm
conclusions regarding the effectiveness of any particular
therapy. Drug-coated balloons remain unavailable for use
in the United States and represent an alternative treatment
modality not evaluated in this series. Finally, although the
scope of this report was to evaluate the outcomes in pa-
tients selected for an endovascular-ﬁrst strategy, the lack
of a surgical comparator cohort limits our ability to deﬁne
the overall role of endovascular therapies as a treatment
strategy for patients with CLI.
CONCLUSIONS
IP occlusion recanalization can be achieved with high
procedural success rates and low complications rates using
standard guidewire and support catheter techniques. In pa-
tients selected for an endovascular strategy, successful IP
occlusion recanalization is associated with increased
amputation-free survival compared with failed IP occlusion
interventions. Further studies should be performed to
compare endovascular recanalization with the outcomes
of distal surgical bypass for patients with IP occlusions.
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